Iovance Biotherapeutics, Inc. (0JDK.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 1B |
| Enterprise Value | 931.33M |
| P/E Ratio | -4.41 |
| PEG Ratio | -0.15 |
| Price/Sales Ratio | 5.08 |
| Price/Book Ratio | 2.35 |
| Enterprise/Revenue | 4.56 |
| Enterprise/EBITDA | -4.05 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | -1.24 |
| Operating Margin | -1.27 |
AD
Management Effectiveness
| Return On Assets | -0.38 |
| Return On Equity | -0.5 |
Income Statement
| Revenue | 263.5M |
| Revenue/Share | 0.68 |
| Gross Profit | 54.38M |
| EBITDA | -362.27M |
| Net Income | -390.98M |
| Diluted EPS | -1.09 |
Balance Sheet
| Total Cash | 313.44M |
| Total Cash/Share | 0.75 |
| Total Debt | 47.78M |
| Total Debt/Equity | 0.07 |
| Current Ratio | 3.6 |
| Book Value Per Share | 1.72 |
Price History
| 52-Week Change | 106.88 |
| 52-Week High | 18.31 |
| 52-Week Low | 3.22 |
| Moving Average 50 Days | 11.04 |
| Moving Average 200 Days | 7.44 |
Statistics
| Average Volume | 53,275 |
| Shares Outstanding | 381.32M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
